Back

Discussion: CXL-1427.

21 May 2016 (14:42 - 14:45)
Organised by:
Congress Presentation Part of: Late Breaking Trials I: Focus on acute heart failure Acute Heart Failure HFA Premium Access HEART FAILURE 2016

12 More presentations in this session

Presentation thumbnail
Bi treatment with hydralazine/nitrates versus placebo in africans admitted with acute heart failure (BA-HEF).
Professor K. Sliwa (Cape Town, ZA)
Presentation thumbnail
Discussion: BA-HEF.
Video
Presentation thumbnail
RELAX-REPEAT: a multicentre, prospective, randomised, double-blind study evaluating the safety and tolerability of repeat doses of serelaxin in patients with chronic heart failure.
Professor J. Teerlink (San Francisco, US)
Slides Video
Presentation thumbnail
Discussion: RELAX-REPEAT.
Video
Presentation thumbnail
Positive hemodynamic effects of CXL-1427, a novel nitroxyl prodrug in advanced heart failure patients.
Professor V. Mitrovic (Nauheim, DE)
Slides Video

Access the full session

Session thumbnail
Late Breaking Trials I: Focus on acute heart failure

The Event

Event poster

HEART FAILURE 2016

21 May 2016 14:42 CET
You may be interested in
thumbnail
Congress Session
Emerging biomarkers-omics in cardiology: beyond the usual suspects
25 August 2023
thumbnail
Congress Presentation
Discussant review - LIBREXIA ACS
29 August 2026
thumbnail
Congress Session
State-of-the-art management for atrial arrhythmia in complex ACHD patients
16 April 2023
thumbnail
Congress Session
Reducing hospitalisations and improving quality of life: why use cardiac contractility modulation (CCM)?
20 May 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources